The Electrospinning Company is developing the Symatix® membrane which is an innovative synthetic amniotic membrane substitute. The membrane is created using electrospinning technology and is designed to overcome the limitation of the Human Amniotic Membrane (HAM).

Human Amniotic Membrane

Human Amniotic Membrane (HAM) is a common product used for treating several ocular surface disorders within ophthalmology and other wound healing applications. Despite being the current gold standard, the failure rate of HAM during surgery is between 33-44% which can increase the patient’s risk of complications post-surgery.

HAM is acquired from elective caesarean patients and in hospitals with the facilities to harvest and post-process the donated tissues. This means that HAM is in limited supply. Furthermore, the use of these human tissues requires stringent serology tests of donors, a special tissue banking facility for storage and extensive traceability measures. All of which drives up health care costs and challenges the accessibility of treatment to patients.

Surface Topography of HAM vs Symatix

Fig. 1 shows the scanning electron micrograph images of Symatix membrane with a similar topography as freeze-dried HAM. 1000 x magnification. Scale bar = 80μm.
Fig. 1 shows the scanning electron micrograph images of Symatix membrane with a similar topography as freeze-dried HAM. 1000 x magnification. Scale bar = 80μm.

Benefits of Symatix membrane:

  • Made from synthetic biomaterial ensuring batch-to-batch consistency
  • Mass scale production capability
  • Easy to handle and can be stored at room temperature
  • Sterile – no risk of disease transmission
  • Versatile – thickness, pore size and degradation duration can be tailored to clinical needs
  • Has the ability to incorporate Active Pharmaceutical Ingredient (API)

Surgical Handling

Fig. 2 shows a sample of the Symatix membrane placed on a rodent eye. The membrane is transparent, wettable and flexible around the eye.
Fig. 2 shows a sample of the Symatix membrane placed on a rodent eye. The membrane is transparent, wettable and flexible around the eye.

Product Pipeline

Fig 1. shows that the Symatix membrane is currently in the preclinical stage.
Fig. 3 shows the Symatix membrane is currently in the preclinical stage and close to completing this stage.

Clinical Advisors

To ensure that the Symatix device handles well in the clinic and delivers the required performance, we are working closely with world-leading experts in ophthalmology. Professor Dua and Dr Sangwan have been part of the Symatix Membrane development from the beginning.

Harminder-Dua

Professor Harminder Dua

Professor of Ophthalmology and Visual Sciences, Faculty of Medicine & Health Sciences

Virender-Singh-Sangwan

Dr. Virender Sangwan

Director of Innovation at Shroff’s Charity Hospital, New Delhi, India

Symatix® is the registered trade mark of The Electrospinning Company Limited in the UK.